Visão geral da empresa
A healthcare solutions provider, iTonic Holdings Ltd. develops and commercializes specialized treatment software and medical devices designed specifically for brachytherapy procedures. The company's proprietary treatment planning system facilitates radioactive particle implantation, a form of radiotherapy utilized to treat cancer patients by placing radioactive sources directly within or near tumor sites. This entity operates within the broader Healthcare sector, specifically focusing on the Medical Devices industry, where it positions itself as a niche player in oncological therapeutic technologies. With a market capitalization of $7.42M, the company represents a small-cap investment, supported by annual revenue of $523,031 and a workforce consisting of 7 employees. These financial figures indicate that iTonic Holdings operates on a very small scale, suggesting a highly specialized business model that relies on high-margin software solutions rather than mass-produced hardware to generate its limited income stream.
Saúde financeira
The company reported a revenue of $523,031 over the trailing twelve months, yet this top-line performance is offset by a net income of $-5,097,901, revealing a significant gap that highlights a substantial negative cost structure and operational losses. This disparity between revenue and profitability is further exacerbated by an EBITDA of $-5,173,649, which indicates that core operating activities are currently generating negative cash flows before financing and tax effects. The free cash flow stands at $-902,183, meaning the company is burning cash and lacks the immediate financial flexibility to fund expansion or R&D without external capital injections. Profitability metrics reflect this distress, with a gross margin of 62.6% demonstrating efficient cost of goods sold, contrasted sharply by an operating margin of -681.9% and a profit margin of 0.0%, which signal severe operating inefficiencies relative to sales volume. Regarding liquidity and leverage, the company holds $2.93M in cash against $142,998 in debt, resulting in a debt-to-equity ratio of 1.76 that suggests a leveraged balance sheet despite the cash buffer. The current ratio of 8.83 indicates a very strong short-term liquidity position, suggesting the firm can easily meet its current liabilities. However, the return on equity is -71.2% and the return on assets is -41.0%, revealing that management is currently destroying shareholder value and failing to generate returns on the capital base.
Avaliação de valorização
Valuation multiples for iTonic Holdings are difficult to interpret using traditional earnings-based metrics due to the lack of profitability, as the trailing P/E ratio is N/A and the forward P/E is also N/A. The absence of a forward P/E implies that the market does not expect immediate earnings recovery, creating a stark difference between current valuation and future earnings trajectory expectations. Instead, the price-to-book ratio is 0.70, indicating that the stock trades at a discount to its book value, which often suggests a market perception of high risk or potential asset undervaluation. Alternative valuation metrics provide a clearer picture, with a price-to-sales ratio of 14.18 and an EV/EBITDA of -0.84, suggesting the market values the company primarily on its revenue generation and software IP rather than current earnings power. The stock's price volatility is extreme, having traded between a 52-week low of $0.25 and a 52-week high of $32.00. Assuming a current price near the upper end of this range for calculation context, the stock has experienced massive price swings, trading at approximately 12,700% above the 52-week low, reflecting the high-risk nature of a micro-cap biotech or device firm. The beta is N/A, meaning there is insufficient historical data to calculate the stock's volatility relative to the broader market, though the price range itself confirms extreme sensitivity to market sentiment.
Growth & Income
Revenue growth for the company is robust at 91.6% year-over-year, while earnings growth is N/A due to the persistent net losses. Since earnings are not growing faster than revenue—in fact, they are negative—the high revenue growth implies that the company is scaling its top line faster than its ability to control operating costs or achieve profitability. As a non-dividend payer, the company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available resources, including the $2.93M cash on hand, back into research, development, and commercialization efforts. This growth and income profile characterizes iTonic as a classic growth-at-any-cost startup, where capital preservation is secondary to market expansion, but the significant cash burn rate poses a long-term sustainability challenge given the lack of earnings growth to support future valuation multiples.